Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia : A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). / Grønhøj, Christian; Jensen, David H; Vester-Glowinski, Peter; Jensen, Siri Beier; Bardow, Allan; Oliveri, Roberto S; Fog, Lea Munthe; Specht, Lena; Thomsen, Carsten; Darkner, Sune; Jensen, Michael; Müller, Vera; Kiss, Katalin; Agander, Tina; Andersen, Elo; Fischer-Nielsen, Anne; von Buchwald, Christian.

I: International Journal of Radiation Oncology, Biology, Physics, Bind 101, Nr. 3, 01.07.2018, s. 581-592.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Grønhøj, C, Jensen, DH, Vester-Glowinski, P, Jensen, SB, Bardow, A, Oliveri, RS, Fog, LM, Specht, L, Thomsen, C, Darkner, S, Jensen, M, Müller, V, Kiss, K, Agander, T, Andersen, E, Fischer-Nielsen, A & von Buchwald, C 2018, 'Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX)', International Journal of Radiation Oncology, Biology, Physics, bind 101, nr. 3, s. 581-592. https://doi.org/10.1016/j.ijrobp.2018.02.034

APA

Grønhøj, C., Jensen, D. H., Vester-Glowinski, P., Jensen, S. B., Bardow, A., Oliveri, R. S., ... von Buchwald, C. (2018). Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). International Journal of Radiation Oncology, Biology, Physics, 101(3), 581-592. https://doi.org/10.1016/j.ijrobp.2018.02.034

Vancouver

Grønhøj C, Jensen DH, Vester-Glowinski P, Jensen SB, Bardow A, Oliveri RS o.a. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). International Journal of Radiation Oncology, Biology, Physics. 2018 jul 1;101(3):581-592. https://doi.org/10.1016/j.ijrobp.2018.02.034

Author

Grønhøj, Christian ; Jensen, David H ; Vester-Glowinski, Peter ; Jensen, Siri Beier ; Bardow, Allan ; Oliveri, Roberto S ; Fog, Lea Munthe ; Specht, Lena ; Thomsen, Carsten ; Darkner, Sune ; Jensen, Michael ; Müller, Vera ; Kiss, Katalin ; Agander, Tina ; Andersen, Elo ; Fischer-Nielsen, Anne ; von Buchwald, Christian. / Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia : A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). I: International Journal of Radiation Oncology, Biology, Physics. 2018 ; Bind 101, Nr. 3. s. 581-592.

Bibtex

@article{57a181f392d74f0884002c25ae3477ca,
title = "Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX)",
abstract = "BACKGROUND: Salivary gland hypofunction and xerostomia are major complications to head and neck radiotherapy. This trial assessed the safety and efficacy of adipose tissue-derived mesenchymal stem cell (ASC) therapy for radiation-induced xerostomia.PATIENT AND METHODS: This randomized, placebo-controlled phase 1/2 trial included 30 patients, randomized in a 1:1 ratio to receive ultrasound-guided transplantation of ASCs or placebo to the submandibular glands. Patients had previously received radiotherapy for a T1-2, N0-2A, human papillomavirus-positive, oropharyngeal squamous cell carcinoma. The primary outcome was the change in unstimulated whole salivary flow rate, measured before and after the intervention. All assessments were performed one month prior (baseline) and one and four months following ASC or placebo administration.RESULTS: No adverse events were detected. Unstimulated whole salivary flow rates significantly increased in the ASC-arm at one (33{\%}; P = .048) and four months (50{\%}; P = .003), but not in the placebo-arm (P = .6 and P = .8), compared to baseline. The ASC-arm symptom scores significantly decreased on the xerostomia and VAS questionnaires, in the domains of thirst (-22{\%}, P = .035) and difficulties in eating solid foods (-2{\%}, P = .008) after four months compared to baseline. The ASC-arm showed significantly improved salivary gland functions of inorganic element secretion and absorption, at baseline and four months, compared to the placebo-arm. Core-needle biopsies showed increases in serous gland tissue and decreases in adipose and connective tissues in the ASC-arm compared to the placebo-arm (P = .04 and P = .02, respectively). MRIs showed no significant differences between groups in gland size or intensity (P < .05).CONCLUSIONS: ASC therapy for radiation-induced hypofunction and xerostomia was safe and significantly improved salivary gland functions and patient-reported outcomes. These results should encourage further exploratory and confirmatory trials.",
author = "Christian Gr{\o}nh{\o}j and Jensen, {David H} and Peter Vester-Glowinski and Jensen, {Siri Beier} and Allan Bardow and Oliveri, {Roberto S} and Fog, {Lea Munthe} and Lena Specht and Carsten Thomsen and Sune Darkner and Michael Jensen and Vera M{\"u}ller and Katalin Kiss and Tina Agander and Elo Andersen and Anne Fischer-Nielsen and {von Buchwald}, Christian",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.ijrobp.2018.02.034",
language = "English",
volume = "101",
pages = "581--592",
journal = "International Journal of Radiation Oncology, Biology, Physics",
issn = "0360-3016",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia

T2 - A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX)

AU - Grønhøj, Christian

AU - Jensen, David H

AU - Vester-Glowinski, Peter

AU - Jensen, Siri Beier

AU - Bardow, Allan

AU - Oliveri, Roberto S

AU - Fog, Lea Munthe

AU - Specht, Lena

AU - Thomsen, Carsten

AU - Darkner, Sune

AU - Jensen, Michael

AU - Müller, Vera

AU - Kiss, Katalin

AU - Agander, Tina

AU - Andersen, Elo

AU - Fischer-Nielsen, Anne

AU - von Buchwald, Christian

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - BACKGROUND: Salivary gland hypofunction and xerostomia are major complications to head and neck radiotherapy. This trial assessed the safety and efficacy of adipose tissue-derived mesenchymal stem cell (ASC) therapy for radiation-induced xerostomia.PATIENT AND METHODS: This randomized, placebo-controlled phase 1/2 trial included 30 patients, randomized in a 1:1 ratio to receive ultrasound-guided transplantation of ASCs or placebo to the submandibular glands. Patients had previously received radiotherapy for a T1-2, N0-2A, human papillomavirus-positive, oropharyngeal squamous cell carcinoma. The primary outcome was the change in unstimulated whole salivary flow rate, measured before and after the intervention. All assessments were performed one month prior (baseline) and one and four months following ASC or placebo administration.RESULTS: No adverse events were detected. Unstimulated whole salivary flow rates significantly increased in the ASC-arm at one (33%; P = .048) and four months (50%; P = .003), but not in the placebo-arm (P = .6 and P = .8), compared to baseline. The ASC-arm symptom scores significantly decreased on the xerostomia and VAS questionnaires, in the domains of thirst (-22%, P = .035) and difficulties in eating solid foods (-2%, P = .008) after four months compared to baseline. The ASC-arm showed significantly improved salivary gland functions of inorganic element secretion and absorption, at baseline and four months, compared to the placebo-arm. Core-needle biopsies showed increases in serous gland tissue and decreases in adipose and connective tissues in the ASC-arm compared to the placebo-arm (P = .04 and P = .02, respectively). MRIs showed no significant differences between groups in gland size or intensity (P < .05).CONCLUSIONS: ASC therapy for radiation-induced hypofunction and xerostomia was safe and significantly improved salivary gland functions and patient-reported outcomes. These results should encourage further exploratory and confirmatory trials.

AB - BACKGROUND: Salivary gland hypofunction and xerostomia are major complications to head and neck radiotherapy. This trial assessed the safety and efficacy of adipose tissue-derived mesenchymal stem cell (ASC) therapy for radiation-induced xerostomia.PATIENT AND METHODS: This randomized, placebo-controlled phase 1/2 trial included 30 patients, randomized in a 1:1 ratio to receive ultrasound-guided transplantation of ASCs or placebo to the submandibular glands. Patients had previously received radiotherapy for a T1-2, N0-2A, human papillomavirus-positive, oropharyngeal squamous cell carcinoma. The primary outcome was the change in unstimulated whole salivary flow rate, measured before and after the intervention. All assessments were performed one month prior (baseline) and one and four months following ASC or placebo administration.RESULTS: No adverse events were detected. Unstimulated whole salivary flow rates significantly increased in the ASC-arm at one (33%; P = .048) and four months (50%; P = .003), but not in the placebo-arm (P = .6 and P = .8), compared to baseline. The ASC-arm symptom scores significantly decreased on the xerostomia and VAS questionnaires, in the domains of thirst (-22%, P = .035) and difficulties in eating solid foods (-2%, P = .008) after four months compared to baseline. The ASC-arm showed significantly improved salivary gland functions of inorganic element secretion and absorption, at baseline and four months, compared to the placebo-arm. Core-needle biopsies showed increases in serous gland tissue and decreases in adipose and connective tissues in the ASC-arm compared to the placebo-arm (P = .04 and P = .02, respectively). MRIs showed no significant differences between groups in gland size or intensity (P < .05).CONCLUSIONS: ASC therapy for radiation-induced hypofunction and xerostomia was safe and significantly improved salivary gland functions and patient-reported outcomes. These results should encourage further exploratory and confirmatory trials.

U2 - 10.1016/j.ijrobp.2018.02.034

DO - 10.1016/j.ijrobp.2018.02.034

M3 - Journal article

VL - 101

SP - 581

EP - 592

JO - International Journal of Radiation Oncology, Biology, Physics

JF - International Journal of Radiation Oncology, Biology, Physics

SN - 0360-3016

IS - 3

ER -

ID: 198226711